Tomer Kariv - 30 Jan 2023 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Sumit Aggarwal, Attorney-in-Fact for Tomer Kariv
Issuer symbol
N/A
Transactions as of
30 Jan 2023
Net transactions value
$0
Form type
4
Filing time
31 Jan 2023, 15:08:40 UTC
Previous filing
30 Nov 2022
Next filing
08 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELOX Stock Options (Right to Buy) Award $0 +2,859 $0.000000 2,859 30 Jan 2023 Common Stock 2,859 $4.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
F2 The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner.

Remarks:

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.